814 reports of this reaction
3.0% of all ACLIDINIUM BROMIDE reports
#4 most reported adverse reaction
ASTHMA is the #4 most commonly reported adverse reaction for ACLIDINIUM BROMIDE, manufactured by Covis Pharma US, Inc. There are 814 FDA adverse event reports linking ACLIDINIUM BROMIDE to ASTHMA. This represents approximately 3.0% of all 27,417 adverse event reports for this drug.
Patients taking ACLIDINIUM BROMIDE who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is a less commonly reported adverse event for ACLIDINIUM BROMIDE, but still significant enough to appear in the safety profile.
In addition to asthma, the following adverse reactions have been reported for ACLIDINIUM BROMIDE:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 814 FDA reports for ACLIDINIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 3.0% of all adverse event reports for ACLIDINIUM BROMIDE, making it a notable side effect.
If you experience asthma while taking ACLIDINIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.